Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$33.9 million.

  • TScan Therapeutics' Free Cash Flow fell 1570.95% to -$33.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$135.9 million, marking a year-over-year decrease of 2285.27%. This contributed to the annual value of -$114.6 million for FY2024, which is 7773.63% down from last year.
  • As of Q3 2025, TScan Therapeutics' Free Cash Flow stood at -$33.9 million, which was down 1570.95% from -$34.5 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Free Cash Flow registered a high of $6.6 million during Q3 2023, and its lowest value of -$39.1 million during Q1 2025.
  • Its 5-year average for Free Cash Flow is -$21.9 million, with a median of -$22.4 million in 2023.
  • Per our database at Business Quant, TScan Therapeutics' Free Cash Flow soared by 13786.3% in 2023 and then crashed by 54389.21% in 2024.
  • Over the past 5 years, TScan Therapeutics' Free Cash Flow (Quarter) stood at -$16.6 million in 2021, then dropped by 4.8% to -$17.4 million in 2022, then plummeted by 39.39% to -$24.2 million in 2023, then dropped by 16.77% to -$28.3 million in 2024, then decreased by 19.75% to -$33.9 million in 2025.
  • Its Free Cash Flow was -$33.9 million in Q3 2025, compared to -$34.5 million in Q2 2025 and -$39.1 million in Q1 2025.